PMID: 42251856

Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

Rosenstock Julio, Billings Liana K, Gajria Reena, Giorgino Francesco, Johansen Nanna Borup, Klein Klara R, Thamattoor Usha K, Buse John B, Jain Akshay B

Lancet (London, England) · 2026

Vol. 408, Issue 10549, pp. 38-51

This entry links to third-party literature. For research use only.